Yeah fair enough, know what you mean. I don't think they were deliberately trying to mislead, think they were just trying to show that in this particular study, on direct comparison when the same targeting ligand, tb161 seemed superior to lu177. It's just pointing out some early evidence that tb161 may be a favourable radioisotope, and that RAD have secured supply of tb161, when no other listed companies do. Agreed, our side of the bargain, the mab(s), still need to be proven, and having supply of the best radioisotope is meaningless if the carrier molecule is crap.
RAD Price at posting:
5.9¢ Sentiment: Hold Disclosure: Held
